AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Prestige Consumer Healthcare Inc.
Video analysis: PBH
All videosNo video analysis for this stock yet. Request one from our team.
News: PBH
Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference
TARRYTOWN, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that Ron Lombardi, Chairman, President, & CEO and Christine Sacco, CFO and COO will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, September 10, 2026 at 12:45 p.m.
Football Stress May Be Following Fans to Bed, According to the Inaugural DenTek® Football Stress Test
National survey commissioned by DenTek, the #1 OTC dental guard brand for nighttime teeth grinding, finds nearly 8 in 10 football fans keep thinking about the game after it ends, with many reporting stress-related behaviors that extend into bedtime. NFL legends Ronde & Tiki Barber join DenTek to encourage fans to recognize when football stress may be affecting more than just game day.
PBH vs. SYK: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Nearly 40,000 eye drops recalled nationwide over possible contamination
Prestige Brand Holdings is recalling 39,060 bottles of certain Clear Eyes drops over sterility concerns, according to a Food and Drug Administration report.
Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts
Amylyx Pharmaceuticals, Inc. is upgraded to Strong Buy after positive phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia [PBH]. Avexitide met its primary endpoint, achieving a 55% reduction in severe hypoglycemic events, with strong statistical significance and a favorable safety profile. Key catalysts include an NDA submission for avexitide in PBH by end-2026 and medical data presentation in 2026; expansion into long-acting GLP-1 antagonist AMX0318 is underway.
PBH or SYK: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Premium Brands Q2 Earnings Call Highlights
Premium Brands TSE: PBH said its revised 2026 outlook reflects timing shifts in U.S. customer programs and the exit of a low-margin Ontario facility, rather than a deterioration in the company's underlying operating assumptions.
